Research
Hormonal
Metformin is the primary first-line oral treatment for type 2 diabetes across all age groups due to its efficacy, versatility, and cost-effectiveness, with benefits extending to cardiovascular and potential anti-neoplastic properties.
Start with metformin as your primary medication. It is the standard, effective, and affordable choice for managing blood sugar. While it may cause mild stomach issues initially, it is generally well-tolerated and helps protect your heart and kidneys over the long term.
GoodSupportsHIGH confidence
Metformin, a standard in diabetes management, continues to serve as the primary, first-line oral treatment across all age groups due to its efficacy, versatility in combination therapy, and cost-effectiveness.
Why this rating
Supported by extensive clinical experience, meta-analyses, and the UKPDS study, though some long-term CV effects lack high-quality evidence.
Source
Drug Therapies for Diabetes
Roni Weinberg Sibony et al. · International Journal of Molecular Sciences · 2023
DOI 10.3390/ijms242417147
narrative_reviewCited 97×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 Receptor Agonists (GLP-1 RA) and SGLT-2 Inhibitors (SGLT-2i) provide significant cardiovascular and renal benefits, with GLP-1 RAs also offering substantial weight loss and HbA1c reduction.Strong
- Sulfonylureas are associated with weight gain, hypoglycemia, and declining long-term efficacy, making them unsuitable as first- or second-line treatments.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →